Alogliptin/metformin

Drug Profile

Alogliptin/metformin

Alternative Names: Alogliptin benzoate/metformin hydrochloride; Inisync; KAZANO; Kazano; Metformin/alogliptin; Nesina Met; SYR-322/metformin; SYR-322MET; TAK-322/metformin; Vipdomet

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Antihyperglycaemics; Biguanides; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 17 Aug 2017 Alogliptin/metformin market licensed to Hikma Pharmaceuticals in Middle East and North Africa
  • 28 Sep 2016 Registered for Type-2 diabetes mellitus in Japan (PO)
  • 30 Apr 2016 Takeda completes a phase I bio-availability trial in volunteers in Russia (NCT02508168)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top